clorgyline has been researched along with Huntington Disease in 1 studies
Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Miralles, M | 1 |
| Ooi, J | 1 |
| Ferrari Bardile, C | 1 |
| Tan, LJ | 1 |
| George, M | 1 |
| Drum, CL | 1 |
| Lin, RY | 1 |
| Hayden, MR | 1 |
| Pouladi, MA | 1 |
1 other study available for clorgyline and Huntington Disease
| Article | Year |
|---|---|
Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.
Topics: Animals; Brain; Clorgyline; Disease Models, Animal; Exploratory Behavior; Hindlimb Suspension; Human | 2016 |